We previously showed that an active immunotherapy strategy, IFN-Kinoid (IFN-K), made up of conjugated IFNα and Keyhole Limpet Hemocyanin (KLH), was successful in preventing systemic lupus erythematosus (SLE)-manifestations and improving survival in New Zealand Black and White (NZB/W) mice (19), by inducing neutralizing anti-IFNα antibodies (Abs). The gene discussed is IFNK; the disease is systemic lupus erythematosus.